SCHEMBL2912369

SCHEMBL2912369

Cc1cccc2cnc(Nc3cccc(Cl)c3)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.56
SRC P12931 1/20 0.53
GRM5 P41594 3/20 0.52
MAOB P27338 2/20 0.52
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
JAK3 P52333 1/20 0.48
MAOA P21397 1/20 0.48
ABL1 P00519 1/20 0.48
BCR P11274 1/20 0.48
PRKCA P17252 1/20 0.48
PRKCD Q05655 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
IGF1R P08069 2/20 0.47
CDK4 P11802 1/20 0.47
CDK2 P24941 1/20 0.47
PTGS1 P23219 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2913599 0.83 KDR (0.56) SYKCDK4CDK2PTGS1PTGS2
SCHEMBL2922769 0.83 SYK (0.67) SYKSRCABL1CDK4CDK2
SCHEMBL2911814 0.83 MAPK10 (0.53) SYKGRM5JAK3CDK4CDK2
SCHEMBL12999377 0.83 ABL1 (0.58) SYKSRCABL1BCRCDK4
SCHEMBL2919611 0.83 L3MBTL1 (0.51) SYKSRCJAK2JAK1JAK3
Hydrochloric Acid SCHEMBL2916265 0.82 ABL1 (0.57) SYKSRCABL1BCRCDK4
SCHEMBL2916276 0.82 SYK (0.45) SYKSRCABL1CDK4CDK2
SCHEMBL2920308 0.80 IDH2 (0.57) HDAC3HDAC1HDAC2HDAC6MAPT
SCHEMBL2917772 0.80 SYK (0.58) SYKGRM5MAOBJAK1JAK3
SCHEMBL12999379 0.80 ABL1 (0.48) SYKSRCJAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K SYK 724/4885SRC 141/4885GRM5 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.